Nevertheless, the observations from this study clearly indicate that PZ-39 may serve as a lead compound for further design and optimization of more specific ABCG2 inhibitors for better treatment of drug resistant human cancers in combinational therapy. The gene discussed is ABCG2; the disease is cancer.